glp 1 inflammation GLP-1 Agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies GLP-1 Therapies May Benefit MPN

43: 146977 De Grandis D, Santoro L, Di Benedetto P

Now their stomachs are paralyzed July 25, 2023 Facial lipoatrophy with semaglutide-related weight loss February 10, 2023 --------------------------------------- Glucagon-like peptide 1 (GLP-1) agonists are medications approved for treatment of diabetes that recently have also been used off label for weight loss.1 Studies have found increased risks of gastrointestinal adverse events (biliary disease,2 pancreatitis,3 bowel obstruction,4 and gastroparesis5) in patients with diabetes.2-5 Because such patients have higher baseline risk for gastrointestinal adverse events, risk in patients taking these drugs for other indications may differ

Hoyo C, et al

In DKD, the high level of HO-1 induced by Nrf2 or hypoxia inducible factor-1 (HIF-1) effectively decreased ROS generation and alleviated kidney injury[133, 134]

In addition to transcriptional markers of endothelial cell activation and increased ROS, we performed protein level analysis of proinflammatory cytokines as well as antioxidants to further elucidate the cellular response to PAGln in a time-dependent manner (Fig